CN101243043B - Ppar受体和egf受体特异性化合物及其盐以及它们在医药领域中的用途 - Google Patents

Ppar受体和egf受体特异性化合物及其盐以及它们在医药领域中的用途 Download PDF

Info

Publication number
CN101243043B
CN101243043B CN2006800300279A CN200680030027A CN101243043B CN 101243043 B CN101243043 B CN 101243043B CN 2006800300279 A CN2006800300279 A CN 2006800300279A CN 200680030027 A CN200680030027 A CN 200680030027A CN 101243043 B CN101243043 B CN 101243043B
Authority
CN
China
Prior art keywords
compound
cells
compounds
pparγ
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800300279A
Other languages
English (en)
Chinese (zh)
Other versions
CN101243043A (zh
Inventor
G·纳卡里
S·巴罗尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Giuliani International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani International Ltd filed Critical Giuliani International Ltd
Publication of CN101243043A publication Critical patent/CN101243043A/zh
Application granted granted Critical
Publication of CN101243043B publication Critical patent/CN101243043B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
CN2006800300279A 2005-07-22 2006-07-24 Ppar受体和egf受体特异性化合物及其盐以及它们在医药领域中的用途 Expired - Fee Related CN101243043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000390A ITRM20050390A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM2005A000390 2005-07-22
PCT/IE2006/000076 WO2007010514A2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field

Publications (2)

Publication Number Publication Date
CN101243043A CN101243043A (zh) 2008-08-13
CN101243043B true CN101243043B (zh) 2013-03-20

Family

ID=37574984

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800300279A Expired - Fee Related CN101243043B (zh) 2005-07-22 2006-07-24 Ppar受体和egf受体特异性化合物及其盐以及它们在医药领域中的用途

Country Status (11)

Country Link
US (2) US8138357B2 (enExample)
EP (1) EP1910275B1 (enExample)
JP (1) JP5193862B2 (enExample)
CN (1) CN101243043B (enExample)
AU (1) AU2006271163B2 (enExample)
BR (1) BRPI0613398A2 (enExample)
CA (1) CA2615978A1 (enExample)
IT (1) ITRM20050390A1 (enExample)
NO (1) NO20080323L (enExample)
NZ (1) NZ566044A (enExample)
WO (1) WO2007010514A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2010213093B2 (en) 2009-02-16 2016-01-07 Nogra Pharma Limited Alkylamido compounds and uses thereof
CN104254327A (zh) * 2012-02-09 2014-12-31 诺格拉制药有限公司 治疗纤维化的方法
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
AR105911A1 (es) 2015-09-03 2017-11-22 Forma Therapeutics Inc Inhibidores de hdac8 bicíclicos fusionados [6,6]
WO2020152350A1 (en) 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
EP4495101A3 (en) * 2019-02-08 2025-04-30 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
WO2025132838A1 (en) 2023-12-20 2025-06-26 Nogra Pharma Limited Acne topical formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211610A (en) * 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
EP0102833A1 (en) * 1982-09-02 1984-03-14 Euroceltique S.A. Carboxylation of metal aryloxides
WO1995031194A1 (en) * 1994-05-11 1995-11-23 Shapiro Howard K Compositions for treatment of chronic inflammatory diseases
CN1370159A (zh) * 1999-06-18 2002-09-18 史密丝克莱恩比彻姆股份公司 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
WO2002095393A2 (en) * 2001-05-24 2002-11-28 National Research Council Of Canada Drug evolution: drug design at hot spots
WO2005012280A1 (en) * 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3444232A (en) * 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
US4036951A (en) * 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
DE3164618D1 (en) * 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
US4933330A (en) * 1987-04-01 1990-06-12 Dak-Laboratoriet Benzoic acid derivatives and use thereof
ES2065980T3 (es) 1988-05-05 1995-03-01 Tillotts Pharma Ag Uso del acido 5-aminosalicilico en el tratamiento de alteraciones dermatologicas.
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) * 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) * 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
EP0604641B1 (en) 1992-06-30 2002-03-20 SHAPIRO, Howard, K. Use of a combination containing an amine or amine-related derivative of benzoic acid and an amino-polysaccharide in the manufacture of a medicament for the treatment of inflammatory diseases
ES2137996T3 (es) * 1992-07-17 2000-01-01 Janssen Pharmaceutica Nv 4-amino-n-(4-metil-4-piperidinil)-2-metoxibenzamidas, su preparacion y su empleo como antagonistas 5-ht2.
US5594151A (en) * 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) * 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
US7098025B1 (en) * 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
AU9002798A (en) * 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040034067A1 (en) * 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
JP3854154B2 (ja) 2000-04-19 2006-12-06 ニューロテック カンパニー リミテッド 中枢神経系の急性及び慢性的損傷に起因した神経変性を防止するための化合物、組成物及び方法
DK1285908T3 (da) 2000-05-29 2008-12-01 Kyorin Seiyaku Kk Substituerede phenylpropionsyrederivater
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
WO2002046161A1 (en) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
FR2822955B1 (fr) * 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
HRP20040350A2 (en) 2001-10-16 2005-06-30 Dr. Reddy's Laboratories Limited NOVEL ?-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR US COMPOUNDS
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) * 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) * 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
JPWO2004082715A1 (ja) * 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
ES2375132T3 (es) * 2003-07-21 2012-02-27 Merck Serono Sa Dicarboxamidas de arilo.
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) * 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2010213093B2 (en) 2009-02-16 2016-01-07 Nogra Pharma Limited Alkylamido compounds and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211610A (en) * 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
EP0102833A1 (en) * 1982-09-02 1984-03-14 Euroceltique S.A. Carboxylation of metal aryloxides
WO1995031194A1 (en) * 1994-05-11 1995-11-23 Shapiro Howard K Compositions for treatment of chronic inflammatory diseases
CN1370159A (zh) * 1999-06-18 2002-09-18 史密丝克莱恩比彻姆股份公司 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
WO2002095393A2 (en) * 2001-05-24 2002-11-28 National Research Council Of Canada Drug evolution: drug design at hot spots
WO2005012280A1 (en) * 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHTISTEL ROUSSEAUX ET AL..INTESTINAL ANTIINFLAMMATORY EFFECT OF 5-AMINOSLICYLIC ACID IS DEPENTDENT ON PEROXISOME PROLIFERATOR-ACTIVATED RECPTOR-γ.《THE JOURNAL OF EXPERIMENTAL MEDICINE》.2005,第201卷(第8期),1205-1215. *
徐新敏等.对氨基水杨酸的新用途.《新疆医学》.2002,第32卷(第2期), *

Also Published As

Publication number Publication date
AU2006271163B2 (en) 2012-03-15
BRPI0613398A2 (pt) 2011-01-11
WO2007010514A3 (en) 2007-03-29
NO20080323L (no) 2008-04-15
AU2006271163A1 (en) 2007-01-25
JP2009502775A (ja) 2009-01-29
EP1910275B1 (en) 2013-02-13
ITRM20050390A1 (it) 2007-01-23
NZ566044A (en) 2012-06-29
WO2007010514A2 (en) 2007-01-25
US20120316230A1 (en) 2012-12-13
CN101243043A (zh) 2008-08-13
CA2615978A1 (en) 2007-01-25
US8450506B2 (en) 2013-05-28
JP5193862B2 (ja) 2013-05-08
US20090118357A1 (en) 2009-05-07
US8138357B2 (en) 2012-03-20
EP1910275A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
US8450506B2 (en) Compounds and their salts specific to the PPAR receptors and the EGF Receptors and their use in the medical field
US8710100B2 (en) Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
BRPI0613396B1 (pt) Composto, uso do mesmo, e, composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130320

Termination date: 20130724